This review addresses the current status of drug therapy for the management of fibromyalgia syndrome (FMS) and is based on interdisciplinary FMS management guidelines, meta-analyses of drug trial data, and observational studies. In the absence of a single gold-standard medication, patients are treated with a variety of drugs from different categories, often with limited evidence.
Drug therapy is not mandatory for the management of FMS. Pregabalin, duloxetine, milnacipran, and amitriptyline are the current first-line prescribed agents but have had a mostly modest effect.
With only a minority of patients expected to experience substantial benefit, most will discontinue therapy because of either a lack of efficacy or tolerability problems. Many drug treatments have undergone limited study and have had negative results.
It is unlikely that these failed pilot trials will undergo future study. However, medications, though imperfect, will continue to be a component of treatment strategy for these patients.
Both the potential for medication therapy to relieve symptoms and the potential to cause harm should be carefully considered in their administration.The desire to take medicine is perhaps the greatest feature which distinguishes man from animals.Sir William Osler (1849-1919)
Author: Winfried HäuserBrian WalittMary-Ann FitzcharlesClaudia Sommer
Credits/Source: Arthritis Research Therapy 2014, 16:201
Published on: 2014-01-17
Tweet
News Provider: EUPB – European Press Bureau
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
There are no comments available. Be the first to write a comment.